<DOC>
	<DOC>NCT01947855</DOC>
	<brief_summary>To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic control on no antidiabetic treatment.</brief_summary>
	<brief_title>Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of type 2 diabetes mellitus prior to informed consent Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are: drugna√Øve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or, pretreated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pretreatment drug only if the dose is equal or less than a half of daily maximum approval dose.) Glycosylated haemoglobin (HbA1c) at Visit 1 (screening) for patients without antidiabetic therapy : HbA1c &gt;=7.0 to =&lt;10.0% for patients with one oral antidiabetic drug : HbA1c &gt;=7.0 to =&lt;9.5% Exclusion criteria: Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dL (&gt;13.3 mmol/L) Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula) Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>